| Date | Title | Description |
| 09.09.2024 | Sirsram Medical announces NMPA approval for DAXXIFY® | Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China
HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical ... |
| 30.08.2024 | Fosun's Management: Globalization + Innovation + Asset-light Operations for Sustained and Stable Profits | HONG KONG and SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- On 29 August 2024, Guo Guangchang, Chairman of Fosun International stated at the Fosun International 2024 interim results presentation that Fosun aims to build a consumer group centered ... |
| 29.08.2024 | Fosun Pharma's Bold Steps in Global Healthcare: A Mid-Year Review | In the bustling world of pharmaceuticals, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, stands as a beacon of innovation and resilience. As the company unveiled its interim results for 2024, the numbers te... |
| 29.08.2024 | Fosun International: Navigating Growth Amidst Challenges | Fosun International Limited has emerged as a beacon of resilience in a turbulent economic landscape. The company recently reported its interim results for the first half of 2024, showcasing a robust performance that defies the odds. With to... |
| 28.08.2024 | Fosun Pharma Announces 2024 Interim Results | Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen
SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"... |
| 28.08.2024 | Fosun Intl 1H Revenue Keeps Growing, Debt Ratio Reduces to 50.2% | HONG KONG, Aug. 28, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended 30 June 2024. During the Reporting Period, the Group's revenue continued to grow, reaching ... |
| 28.08.2024 | Fosun Int'l: Total Revenue for 1H2024 Reaches RMB97.84 Bn, Industrial Operation Profit Amounts to RMB 3.47 Bn | Powered by Core Strengths, Focus on Core Businesses & Reinforce Organic Growth Momentum
2024 Interim Results Highlights:
Total revenue maintained growth, reaching RMB97.84 billion;
Industrial operation profit maintained growth, reaching... |
| 28.08.2024 | Fosun Pharma Announces 2024 Interim Results | Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen
SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"... |
| 15.08.2024 | Sisram Medical to Report H1 2024 Financial Results on August 21 and Hold a Conference Call on August 22 | H1 2024 conference call to be held on August 22, at 8:30 a.m. Eastern Time
HONG KONG, Aug. 15, 2024 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries refer... |
| 30.07.2024 | Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors | SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A fu... |
| 30.07.2024 | Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors | SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A fu... |
| 27.07.2024 | Fosun's Globalization Journey: A Path to Profit and Influence | Fosun International is on a mission. The company is weaving a tapestry of globalization, thread by thread, across continents. Under the leadership of Guo Guangchang, Fosun is not just expanding; it’s evolving. This journey began in 2007 whe... |
| 25.07.2024 |
Intuitive’s president is now also on the board | Intuitive President Dave Rosa. [Image from Intuitive Surgical]Intuitive Surgical (Nasdaq: ISRG) + announced that it has appointed President Dave Rosa to its board of directors.
Rosa’s appointment, made yesterday, makes him the second Intuit... |
| 23.07.2024 | Guo Guangchang: Fosun Firmly Advances its Globalization Strategy | HONG KONG, July 23, 2024 /PRNewswire/ -- "In the future, Fosun will continue to firmly advance its globalization strategy, transforming its globalization capability into sustained profit growth." Guo Guangchang, Chairman of Fosun ... |
| 23.07.2024 | Guo Guangchang: Fosun Firmly Advances its Globalization Strategy | HONG KONG, July 23, 2024 /PRNewswire/ -- "In the future, Fosun will continue to firmly advance its globalization strategy, transforming its globalization capability into sustained profit growth." Guo Guangchang, Chairman of Fosun ... |
| 08.07.2024 | Fosun International Ranks Among China's Top 100 ESG Listed Companies, Topping the Composite Industry as the ESG Leader | HONG KONG, July 8, 2024 /PRNewswire/ -- On the afternoon of 30 June 2024, the Financial Program Center of China Media Group (CMG) officially released the "China ESG (Corporate Social Responsibility) 2024 ESG Action Report" in Beij... |
| 07.07.2024 | Fosun International Ranks Among China's Top 100 ESG Listed Companies, Topping the Composite Industry as the ESG Leader | HONG KONG, July 7, 2024 /PRNewswire/ -- On the afternoon of 30 June 2024, the Financial Program Center of China Media Group (CMG) officially released the "China ESG (Corporate Social Responsibility) 2024 ESG Action Report" in Beij... |
| 23.05.2024 | Guo Guangchang: Fosun Steadfastly Focuses on Innovation + Globalization | HONG KONG, May 23, 2024 /PRNewswire/ -- The 4th BEYOND International Technology Innovation Expo (BEYOND Expo 2024) commenced with a spectacular opening ceremony on 22 May at the Venetian Theatre in the Venetian Macao. At the opening ceremon... |
| 23.05.2024 | Guo Guangchang: Fosun Steadfastly Focuses on Innovation + Globalization | HONG KONG, May 23, 2024 /PRNewswire/ -- The 4th BEYOND International Technology Innovation Expo (BEYOND Expo 2024) commenced with a spectacular opening ceremony on 22 May at the Venetian Theatre in the Venetian Macao. At the opening ceremon... |
| 26.04.2024 | Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa | SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO ... |
| 02.04.2024 | Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY | HONG KONG and SHANGHAI, April 2, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its an... |
| 15.03.2024 | /C O R R E C T I O N -- Sisram Medical Ltd/ | In the news release, Sisram Medical to Report FY2023 Financial Results on March 20 and Hold a Conference Call on March 21, issued on 14-Mar-2024 by Sisram Medical Ltd over PR Newswire, we are advised by the company that regarding the time, ... |
| 12.03.2024 | Ardelyx, Inc. Reports Employment Inducement Grants | WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medi... |
| 14.12.2023 | Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility ... | SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase I... |
| 30.08.2023 | Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure | SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During... |
| 09.08.2023 | ZuriMED closes CHF 14.5 million Series A round | |
| 06.06.2023 | Fosun Pharma Participates in 2023 BIO International Convention to Demonstrate its Global Innovation Capabilities | BOSTON, June 6, 2023 /PRNewswire/ -- From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention ("BIO 2023") will be held in Boston, Massachusetts, USA. The BIO International Convention is the world's larg... |
| 06.06.2023 | Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa | ABIDJAN, Côte d'Ivoire, June 6, 2023 /PRNewswire/ -- To support stronger healthcare delivery and outcomes in West Africa, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma or the Company, stock code: 600196.SH; 02196.HK) today a... |
| 10.05.2023 | Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements | MACAU, May 10, 2023 /PRNewswire/ -- From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023 is being held at the Venetian Macau Convention and Exhibition Center. This year is the thi... |
| 26.04.2023 | Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative | SHANGHAI, April 26, 2023 /PRNewswire/ -- On April 25, 2023, World Health Organization (WHO) gave as the theme for World Malaria Day 2023 Time to deliver zero malaria: invest, innovate, implement. Within this theme, WHO will mainly focus on ... |
| 28.03.2023 | Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement | Performance Highlights:
During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable to owners of the parent was RMB 3.873 bill... |
| 07.01.2023 | Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US | PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently devel... |
| 07.01.2023 | Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US | PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently devel... |
| 28.11.2022 | Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents | SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original... |
| 26.09.2022 | Fosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product | PRINCETON, N.J., Sept. 26, 2022 /PRNewswire/ -- Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate (SPSB) liquid produ... |
| 30.08.2022 | Fosun Pharma Announces 2022 Interim Results | Stable Revenue Growth and Recurring Income, Elevating the Revenue Contribution of New Products, and Accelerating International Layout
Highlights:
Revenue for the first half of 2022 amounted to RMB21,340 million, an increase of 25.88% YOY;
N... |
| 20.05.2022 | VerImmune and Fosun Pharma enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China | WASHINGTON (PRWEB) May 20, 2022
VerImmune Inc. (“VerImmune”), a privately-held biotechnology company developing a novel therapeutic virus-inspired particle (ViP) modality that redirects the body’s pre-existing immunity against viral pathoge... |
| 25.04.2022 | World Malaria Day: Fosun Pharma's Self-Developed Artemisinin Series Become Symbol of China's Innovative Medicines | Together We Build a Malaria-Free World
SHANGHAI, April 25, 2022 /PRNewswire/ -- World Malaria Day on April 25, is an occasion that aims to promote global malaria prevention and control. This year, World Malaria Day is marked under the theme... |
| 14.04.2022 | Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control | SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) A... |
| 23.03.2022 | Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively | The Proportion of Revenue from Innovative Products Continues to Increase
Highlights:
Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY;
The proportion of revenue from new products as ... |
| 25.01.2022 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION-INVESTMENT AGREEMENT IN RELATION TO CAPITAL INCREASE IN THE TARGET（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 24.01.2022 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION REGARDING THE TARGET FUND LPA AND CONTINUING CONNECTED TRANSACTION REGARDING THE TARGET FUND MANAGEMENT AGREEMENT AND FURTHER INFORMATION ON CONNE... | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 19.01.2022 | Fosun International : Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets | Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
Release Time：2022-01-18Author：Source: Pageviews：
SHANGHAI, CHINA and, NEW YORK, USA, January... |
| 07.01.2022 | Shanghai Fosun Pharmaceutical : ENTERING INTO TARGET FUND LPA AND POSSIBLE CONTINUING CONNECTED TRANSACTION REGARDING THE ENTERING INTO THE TARGET FUND MANAGEMENT AGREEMENT | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 04.01.2022 | Shanghai Fosun Pharmaceutical : APPOINTMENT OF VICE CHAIRMAN（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 04.01.2022 | Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2021(H SHARES) | FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities
For the month ended: 31 December 2021 Status: New Submission
To : Hong Kong Exchanges... |
| 28.12.2021 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION – ENTERING INTO THE CAPITAL INCREASE AGREEMENT（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 24.12.2021 | Shanghai Fosun Pharmaceutical : FURTHER INFORMATION ON CONNECTED TRANSACTION REGARDING THE ENTERING INTO THE SHARE TRANSFER AGREEMENT (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 17.12.2021 | Shanghai Fosun Pharmaceutical : FURTHER INFORMATION ON CONNECTED TRANSACTION REGARDING THE ENTERING INTO THE EQUITY TRANSFER AGREEMENT (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 09.12.2021 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION - ENTERING INTO THE SHARE TRANSFER AGREEMENT | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 09.12.2021 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION - ENTERING INTO THE EQUITY TRANSFER AGREEMENT | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 03.12.2021 | Fosun International : Pharma Participates in the BEYOND Expo Presents innovation-driven ecological layout of the healthcare industry | Fosun Pharma Participates in the BEYOND Expo Presents innovation-driven ecological layout of the healthcare industry
Release Time：2021-12-03Author：Source: Pageviews：
(2 December 2021,Macao SAR, China) From 2 to 4 December, 2021, focusing on... |
| 01.12.2021 | Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2021(H SHARES) | FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities
For the month ended: 30 November 2021 Status: New Submission
To : Hong Kong Exchanges... |
| 24.11.2021 | Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT REGARDING THE ESTABLISHMENT OF INVESTMENT FUNDS AND POSSIBLE CONTINUING CONNECTED TRANSACTION REGARDING THE ENTERING INTO THE FUND MANAGEMENT AGR... | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 16.11.2021 | Shanghai Fosun Pharmaceutical : (1) EXTENSION OF AUTHORISATION PERIOD AND CHANGE OF AUTHORISED PERSON FOR THE PROPOSED SHANGHAI HENLIUS LISTING (2) ELECTION OF EXECUTIVE DIRECTORS AND NOTICE OF EGM | THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION
If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank mana... |
| 09.11.2021 | VOLUNTARY ANNOUNCEMENT-ENTERING INTO THE EQUITY TRANSFER AGREEMENT (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 09.11.2021 | (1) RESIGNATION OF NON-EXECUTIVE DIRECTORS (2) PROPOSED APPOINTMENTS OF EXECUTIVE DIRECTORS AND (3) CHANGE IN THE COMPOSITION OF BOARD COMMITTEE (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 01.11.2021 | MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2021(H SHARES) | FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities
For the month ended: 31 October 2021 Status: New Submission
To : Hong Kong Exchanges ... |
| 27.10.2021 | Fosun Pharma Announces Its Results for the First Three Quarters of Fiscal 2021 Continues to Strengthen Commercialization Capabilities Net Profit Attributable to Shareholders of the Listed Company Incr... | （26 October 2021, Shanghai, China）26 October 2021, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare gr... |
| 27.10.2021 | VOLUNTARY ANNOUNCEMENT-ACQUISITION OF EQUITY INTEREST IN THE TARGET COMPANY AND CAPITAL INCREASE AND GRANT OF PUT OPTION（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 26.10.2021 | CONNECTED TRANSACTIONS-ENTERING INTO THE EQUITY TRANSFER AGREEMENTS REGARDING THE ACQUISITION OF INTEREST IN A SUBSIDIARY（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 14.10.2021 | Shanghai Fosun Pharmaceutical : DATE OF BOARD MEETING（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 11.10.2021 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION - FORMATION OF JOINT VENTURE (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 30.09.2021 | Shanghai Fosun Pharmaceutical : DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN SUBSIDIARIES | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 10.09.2021 | Shanghai Fosun Pharmaceutical : PROPOSED ADOPTION OF RSU SCHEME BY A SUBSIDIARY （H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 24.08.2021 | Shanghai Fosun Pharmaceutical : Fosun Pharma Announces 2021 Interim Results Innovative Products Continuously Launched with International Operation Capability Further Improved | Highlights：
Revenue amounted to RMB16,952 million, a year-on-year increase of 20.85%, of which, the income from regions outside Chinese Mainland and overseas countries accounted for 30.66%.
The net profit attributable to shareholders of the... |
| 24.08.2021 | Fosun Pharma : Announces 2021 Interim Results | Innovative Products Continuously Launched with International Operation Capability Further Improved
Highlights：
Revenue amounted to RMB16,952 million, a year-on-year increase of 20.85%, of which, the income from regions outside Chinese Mainl... |
| 23.08.2021 | Shanghai Fosun Pharmaceutical : Sisram Medical Ltd, Announces Its Interim Results for the First Half of 2021 Accelerating its Wellness Eco-system Establishment, Harnessing Science and Technology to Le... | Hong Kong, August 22, 2021 -- Sisram Medical Ltd ('Sisram'; stock code: 1696.HK; together with its subsidiaries referred as the 'Group'), an operational holding company specializing in medical aesthetics technology for wellness, today annou... |
| 23.08.2021 | Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT-DISPOSAL OF EQUITY INTEREST IN AN INVESTEE COMPANY (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 20.08.2021 | Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT – ENTERING INTO THE INVESTMENT AGREEMENT (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 10.08.2021 | Shanghai Fosun Pharmaceutical : Date of Board Meeting (H SHARES) | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 15.07.2021 | Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa | SUZHOU, China, July 15, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development")... |
| 15.07.2021 | Kintor Pharmaceutical : Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa | SUZHOU, China, July 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development")... |
| 14.07.2021 | Shanghai Fosun Pharmaceutical : POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2021 SECOND EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, 14 JULY 2021（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 02.07.2021 | Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2021(H SHARES) | Monthly Return of Equity Issuer on Movements in Securities
For the month ended
(dd/mm/yyyy) :30/06/2021
To : Hong Kong Exchanges and Clearing Limited
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Name of Issuer (a joint stock limited comp... |
| 22.06.2021 | Shanghai Fosun Pharmaceutical : Proxy Forms | 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02196)
FORM OF PROXY FOR HOLDERS OF H SHARES
F... |
| 22.06.2021 | Shanghai Fosun Pharmaceutical : NOTICE OF THE 2021 SECOND EXTRAORDINARY GENERAL MEETING | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 22.06.2021 | Shanghai Fosun Pharmaceutical : REPORT ON THE USE OF PROCEEDS PREVIOUSLY RAISED AND NOTICE OF EGM | THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION
If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank mana... |
| 10.06.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION - ENTERING INTO THE PURCHASE AGREEMENT REGARDING THE ACQUISITION OF INTEREST IN A SUBSIDIARY （H S... | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 09.06.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : CONTINUING CONNECTED TRANSACTIONS - (1) ENTERING INTO CQ PHARMA MUTUAL SUPPLY AGREEMENT (2) ENTERING INTO FRAMEWORK TEN... | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 01.06.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 MAY 2021(H SHARES) | Monthly Return of Equity Issuer on Movements in Securities
For the month ended
(dd/mm/yyyy) :31/05/2021
To : Hong Kong Exchanges and Clearing Limited
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Name of Issuer (a joint stock limited comp... |
| 01.06.2021 | Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 MAY 2021(H SHARES) | Monthly Return of Equity Issuer on Movements in Securities
For the month ended
(dd/mm/yyyy) :31/05/2021
To : Hong Kong Exchanges and Clearing Limited
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Name of Issuer (a joint stock limited comp... |
| 31.05.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : DISPOSAL OF EQUITY INTEREST IN SUBSIDIARY | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 31.05.2021 | Shanghai Fosun Pharmaceutical : DISPOSAL OF EQUITY INTEREST IN SUBSIDIARY | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 31.05.2021 | Shanghai Fosun Pharmaceutical : FORMATION OF JV | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 31.05.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : FORMATION OF JV | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 09.05.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : ENTERING INTO THE TERM SHEET IN RELATION TO THE FORMATION OF A JOINT VENTURE | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 05.05.2021 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTIONS ENTERING INTO EQUITY TRANSFER AND LOAN ASSIGNMENT CONTRACT AND NOTICE OF EGM | THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION
If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank mana... |
| 27.04.2021 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTIONS ENTERING INTO EQUITY TRANSFER AND LOAN ASSIGNMENT CONTRACT | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 27.04.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTIONS ENTERING INTO EQUITY TRANSFER AND LOAN ASSIGNMENT CONTRACT | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 14.04.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : DATE OF BOARD MEETING（H SHARES） | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 07.04.2021 | Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2021(H SHARES) | Monthly Return of Equity Issuer on Movements in Securities
For the month ended
(dd/mm/yyyy) :31/03/2021
To : Hong Kong Exchanges and Clearing Limited
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Name of Issuer (a joint stock limited comp... |
| 07.04.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2021(H SHARES) | Monthly Return of Equity Issuer on Movements in Securities
For the month ended
(dd/mm/yyyy) :31/03/2021
To : Hong Kong Exchanges and Clearing Limited
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Name of Issuer (a joint stock limited comp... |
| 30.03.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : Fosun Pharma Announces 2020 Annual Results Multiple Innovative Products Launched with Significant Improvement in the Ca... | (29 March 2021, Shanghai, China) 29 March 2021, Shanghai Fosun Pharmaceutical (Group) Co., Ltd ('Fosun Pharma' or 'the Group'; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced its annual results for the year ... |
| 29.03.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Fosun Pharma : Announces 2020 Annual Results | Multiple Innovative Products Launched with
Significant Improvement in the Capability of Global Commercialization
Net Profit Attributable to Shareholders After Extraordinary G/L Increases 21.65% YOY to RMB2,718 Million
SHANGHAI, March 29, 20... |
| 04.02.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION - FORMATION OF THE JV COMPANY | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 04.02.2021 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION - FORMATION OF THE JV COMPANY | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 01.02.2021 | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2021(H SHARES) | Monthly Return of Equity Issuer on Movements in Securities
For the month ended
(dd/mm/yyyy) :31/01/2021
To : Hong Kong Exchanges and Clearing Limited
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Name of Issuer (a joint stock limited comp... |
| 01.02.2021 | Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2021(H SHARES) | Monthly Return of Equity Issuer on Movements in Securities
For the month ended
(dd/mm/yyyy) :31/01/2021
To : Hong Kong Exchanges and Clearing Limited
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Name of Issuer (a joint stock limited comp... |
| 28.12.2020 | Shanghai Fosun Pharmaceutical : CONNECTED TRANSACTION - ENTERING INTO THE PARTNERSHIP AGREEMENT REGARDING ESTABLISHMENT OF A FUND AND POSSIBLE CONTINUING CONNECTED TRANSACTION - REGARDING THE FUND MAN... | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
